CN105878173B - A kind of Sodium Aescinate liniment - Google Patents
A kind of Sodium Aescinate liniment Download PDFInfo
- Publication number
- CN105878173B CN105878173B CN201610227303.6A CN201610227303A CN105878173B CN 105878173 B CN105878173 B CN 105878173B CN 201610227303 A CN201610227303 A CN 201610227303A CN 105878173 B CN105878173 B CN 105878173B
- Authority
- CN
- China
- Prior art keywords
- liniment
- sodium aescinate
- aescinate
- sodium
- mass ratio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a kind of Sodium Aescinate liniments, it is made of following ingredients：The solvent that Sodium Aescinate 0.1~2%, thickener 0.1~5%, penetrating agent 1~5%, pH are 5~6 is surplus.The present invention has many advantages, such as that Transdermal absorption effect is good, stability is good, skin irritation is small.
Description
Technical field
The invention belongs to field of pharmaceutical preparations, and in particular to a kind of Sodium Aescinate liniment.
Background technology
Sodium Aescinate is carried from the dry mature seed buckeye of Aesculus (Aesculus Wilsonii Rehd.)
The saponin(e sodium salt taken.Buckeye is 2015 editions conventional Chinese medicines recorded of Chinese Pharmacopoeia, has soothing the liver, qi-regulating and stomach, relieves pain, kills
Worm and other effects.Modern pharmacology research, which proves it also, has the function of anti-inflammatory, swollen, impervious, anticancer of subsiding a swelling.Research has shown that, seven leaves
Two kinds of aglycons of Protoescigenin and barringtogenol C sapogenins are mainly contained in saponin(e sodium, the higher ingredient of content is seven leaves
Saponin A, B, C, D.Sodium Aescinate can reduce pathologic capillary permeability and increase, and increase intravenous tension, reduce inflammatory object
Matter is oozed out, and is had the effects that anti-inflammatory, detumescence, analgesic, is improved blood circulation, acute and closed soft tissue injury is promoted to restore.
Sodium Aescinate oral administration biaavailability is not high, and injection is larger to blood vessel irritation, and topical administration keeps drug logical
The osmosis for crossing skin reaches internal body, has the following advantages that：1. percutaneous dosing can avoid the first pass effect and medicine of liver
Degradation of the object in gastrointestinal tract, drug absorption are not influenced by gastrointestinal factors, reduce the individual difference of medication；2. single administration
Drug can be made to enter with constant rate for a long time internal, reduce administration number of times, extend dosing interval；3. avoid take orally to
Blood concentration peak valley phenomenon, reduces toxicity caused by medicine etc..
But existing Sodium Aescinate liniment has the disadvantages that：1. Transdermal absorption effect is bad；2. stability is poor,
Aescinate A, B, C, D changes of contents are big；3. pair skin irritation is larger.
Invention content
The purpose of the present invention is being directed to disadvantages mentioned above existing for existing Sodium Aescinate liniment, a kind of Transdermal absorption effect is provided
Fruit is good, property is stable, skin irritation is small, can be used for treating the Sodium Aescinate liniment of acute and closed soft tissue injury.
Sodium Aescinate liniment provided by the present invention is by following weight proportion at being grouped as：
The thickener be selected from non-ionic celluloses ether, polyethylene glycol, polyvinylpyrrolidone, polyvinyl alcohol, gelatin,
Chitosan, carbomer it is one or more, the non-ionic celluloses ether refer to methylcellulose, carboxymethyl cellulose,
Hydroxyethyl cellulose, hydroxypropyl methyl cellulose etc..
The penetrating agent is selected from propylene glycol, borneol, Laurocapram, peppermint oil, eucalyptus oil, decyl methyl sulfoxide, lemon
It is one or more in alkene；
The solvent is the ethanol water that mass ratio is 30~60%.
Preferably, the Sodium Aescinate liniment by following weight proportion at being grouped as：
It is further preferred that the pH of the solvent is 5.5.
It is further preferred that the ethanol water that it is 40~60% that the solvent, which is mass percent,.
It is further preferred that the thickener is non-ionic celluloses ether and polyvinyl alcohol.
It is further preferred that the non-ionic celluloses ether is hydroxypropyl methyl cellulose, the hydroxypropyl methyl is fine
The mass ratio of dimension element and polyvinyl alcohol is 1~3: 1.
It is further preferred that the penetrating agent is propylene glycol and eucalyptus oil, the mass ratio of the propylene glycol and eucalyptus oil is 5
~10: 1.
The beneficial effects of the invention are as follows：
1) Transdermal absorption effect is good：There is 40% or more drug to pass through Cutaneous permeation to body in the short period after medication
It is interior, to ensure that the rapid performance of drug effect；
2) stability is good：Under high temperature and illumination condition, Aescinate A, B, C, D changes of contents are smaller；
3) skin irritation is small：It is nonirritant to rabbit intact skin.
Description of the drawings
Fig. 1 is Sodium Aescinate liniment accumulation transmitance-time plot.
Fig. 2 is the HPLC chromatogram of Sodium Aescinate liniment.
Specific implementation mode
Below by way of specific implementation mode, the present invention is described in detail.
Embodiment 1
A kind of Sodium Aescinate liniment, by following weight proportion at being grouped as：
The thickener is polyvinylpyrrolidone；
The penetrating agent is Laurocapram；
The solvent is the ethanol water that mass ratio is 30%.
Preparation method is as follows：
The ethanol water for taking 30%, is 5 with winestone acid for adjusting pH, Sodium Aescinate then is added, polyethylene ratio coughs up alkane
Ketone and Laurocapram, stirring and dissolving to get.
Embodiment 2
A kind of Sodium Aescinate liniment, by following weight proportion at being grouped as：
The thickener is selected from gelatin and carbomer, and the mass ratio of the gelatin and carbomer is 1: 1；
The penetrating agent is selected from borneol and limonene, and the mass ratio of the borneol and limonene is 2: 1；
The solvent is the ethanol water that mass ratio is 60%.
Preparation method is as follows：
The ethanol water for taking 60% is 6 with salt acid for adjusting pH, Sodium Aescinate, gelatin, carbomer, ice is then added
Piece, limonene, stirring and dissolving to get.
Embodiment 3
A kind of Sodium Aescinate liniment, by following weight proportion at being grouped as：
The thickener is hydroxypropyl methyl cellulose and polyvinyl alcohol, the hydroxypropyl methyl cellulose and polyvinyl alcohol
Mass ratio be 2: 1；
The penetrating agent is propylene glycol and eucalyptus oil, and the mass ratio of the propylene glycol and eucalyptus oil is 6: 1.
The solvent is the ethanol water that mass ratio is 40%.
Preparation method is as follows：
40% ethanol water is taken, it is 5.5 to adjust pH, and Sodium Aescinate is then added, hydroxypropyl methyl cellulose, gathers
Vinyl alcohol, propylene glycol, eucalyptus oil, stirring and dissolving to get.
Embodiment 4
A kind of Sodium Aescinate liniment, by following weight proportion at being grouped as：
The thickener is methylcellulose and polyethylene glycol, and the mass ratio of the methylcellulose and polyethylene glycol is
2.5∶1；
The penetrating agent is peppermint oil and eucalyptus oil, and the mass ratio of the peppermint oil and eucalyptus oil is 5: 1；
The solvent is the ethanol water that mass ratio is 50%.
Preparation method is as follows：
50% ethanol water is taken, it is 5.8 to adjust pH, and Sodium Aescinate, methylcellulose, poly- second two is then added
Alcohol, peppermint oil, eucalyptus oil, stirring and dissolving to get.
Embodiment 5
A kind of Sodium Aescinate liniment, by following weight proportion at being grouped as：
The thickener is gelatin；
The penetrating agent is propylene glycol and Laurocapram, and the mass ratio of the propylene glycol and Laurocapram is 9: 1；
The solvent is the ethanol water that mass ratio is 55%.
Preparation method is as follows：
55% ethanol water is taken, it is 5.2 to adjust pH, and Sodium Aescinate, gelatin, propylene glycol, bay nitrogen is then added
Tall and erect ketone, stirring and dissolving to get.
Test example
1. Transdermal absorption is tested
SD rats are taken, using 10%Na2S aqueous solutions take off except back wool, and next day, disconnected neck was put to death, and cut skin of back immediately,
Subcutaneous tissue and fat are rejected, after physiological saline is rinsed well repeatedly, is cut into appropriately sized, inspection skin integrity.Using changing
Good Franz vertical double-chambers diffusion cell (effective area 2.92cm2), the rat skin handled well is fixed on to two Room of diffusion cell
Between, stratum corneum side is to supply chamber.0.5mL is taken to be placed in supply chamber Sodium Aescinate liniment precision prepared by Examples 1 to 5,
7mL receiving liquids are added into receiving chamber, receiving liquid is PBS buffer solution (0.01M, pH7.4).Water bath with thermostatic control is set as 32 DEG C, with
150r/min magnetic agitations.Respectively at 0.5,1,2,4,6,8,12, take 0.5mL receiving liquids for 24 hours, while it is slow to supplement 0.5mL PBS
Fliud flushing takes 20 μ L sample introductions to measure Aescinate A peak area after 0.45 μm of membrane filtration, calculates drug concentration.
HPLC chromatogram condition is as follows：Stationary phase is Ultimate C18 (5 μm, 4.6 × 250mm), and mobile phase is acetonitrile：
0.55% phosphate aqueous solution (38：62), Detection wavelength 220nm, flow velocity 1.0mL/min, 35 DEG C of column temperature, 20 μ L of sample size.
Transmitance-time graph the result is shown in Figure 1 is accumulated, percutaneous penetration is shown, Sodium Aescinate liniment transdermal effect
Preferably, there is in the short period 40% or more drug by Cutaneous permeation to internal after medication, to ensure that the fast of drug effect
Speed plays.
2. study on the stability
Sodium Aescinate liniment prepared by Example 1~5 carries out study on the stability.Sodium Aescinate liniment stability is tried
The condition and method tested mainly refer to according to 2015 editions two annex, Ⅺ XC bulk pharmaceutical chemicals of Chinese Pharmacopoeia with pharmaceutical preparation stability test
Lead the requirement of principle.Aescinate A, B, C, D content are measured using HPLC methods, during HPLC chromatogram condition is tested with Transdermal absorption
Chromatographic condition is identical, system suitability requirement：Number of theoretical plate is not less than 3500 based on Aescinate A peak, Aescinate A peak and seven
The separating degree at the peaks leaf saponin(e B, Aescinate B peak and the peaks otoginsenoside C should all meet regulation.Chromatogram is shown in Fig. 2, retention time
The peak of 18.013min, 21.119min, 25.121min and 28.397min correspond to Aescinate A, B, C and D respectively.
Study on the stability experimental result is shown in Table 1.
1 study on the stability of table
As shown in Table 1, under high temperature and illumination condition, Aescinate A, B, C and D in liniment prepared by Examples 1 to 5
Changes of contents very little shows that Sodium Aescinate liniment stability provided by the invention is good.
3. skin irritation is investigated
Healthy rabbits (2.0 ± 0.2kg) 20 are taken, are randomly divided into 5 groups, every group of half male and half female investigates Examples 1 to 5 system
The skin irritation of standby liniment.Before administration for 24 hours, animal backbone diamond wool is taken off with 10% sodium sulfide solution, is gone per side
Hair range about 3cm × 3cm, can not damage epidermis.Experiment is using androgynous left and right sides Self-control method.Distinguish in left and right side unhairing area
Give liniment and water.2 times a day, successive administration one week washed away residual test medicine in the 8th day with warm water.Respectively at removal medicine
1 after object, 24,48,72h observations medicine-feeding parts situations such as whether there is or not erythema and oedema, record occurs and recovery situation, time, gives
Scoring.
2 liniment rabbit skin irritation test result (n=4) of table
As shown in Table 2, after a week, family's rabbit skin only slightly Sodium Aescinate liniment continuous use provided by the invention occurs
Erythema and oedema, wherein embodiment 3 do not find the allergic reactions such as erythema, oedema.The result shows that Sodium Aescinate liniment is to family
Rabbit intact skin irritation is smaller.
Claims (7)
1. a kind of Sodium Aescinate liniment, it is characterised in that by following weight proportion at being grouped as：
It is poly- that the thickener is selected from non-ionic celluloses ether, polyethylene glycol, polyvinylpyrrolidone, polyvinyl alcohol, gelatin, shell
It is sugared, carbomer one or more；
The penetrating agent is in propylene glycol, borneol, Laurocapram, peppermint oil, eucalyptus oil, decyl methyl sulfoxide, limonene
It is one or more；
The solvent is the ethanol water that mass ratio is 30~80%.
2. Sodium Aescinate liniment according to claim 1, it is characterised in that by following weight proportion at being grouped as：
3. Sodium Aescinate liniment according to claim 1 or 2, it is characterised in that：The pH of the solvent is 5.5.
4. Sodium Aescinate liniment according to claim 1 or 2, it is characterised in that：The solvent is that mass percent is
40~60% ethanol water.
5. Sodium Aescinate liniment according to claim 1 or 2, it is characterised in that：The thickener is that nonionic is fine
The plain ether of dimension and polyvinyl alcohol.
6. Sodium Aescinate liniment according to claim 5, it is characterised in that：The non-ionic celluloses ether is hydroxypropyl
The mass ratio of ylmethyl cellulose, the hydroxypropyl methyl cellulose and polyvinyl alcohol is 1~3: 1.
7. Sodium Aescinate liniment according to claim 1 or 2, it is characterised in that：The penetrating agent is propylene glycol and eucalyptus
The mass ratio of leaf oil, the propylene glycol and eucalyptus oil is 5~10: 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610227303.6A CN105878173B (en) | 2016-04-13 | 2016-04-13 | A kind of Sodium Aescinate liniment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610227303.6A CN105878173B (en) | 2016-04-13 | 2016-04-13 | A kind of Sodium Aescinate liniment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105878173A CN105878173A (en) | 2016-08-24 |
| CN105878173B true CN105878173B (en) | 2018-10-19 |
Family
ID=57013250
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610227303.6A Active CN105878173B (en) | 2016-04-13 | 2016-04-13 | A kind of Sodium Aescinate liniment |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105878173B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109200015A (en) * | 2017-07-07 | 2019-01-15 | 海南皇隆制药股份有限公司 | A kind of amikacin externally used solution and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1931176A (en) * | 2005-07-15 | 2007-03-21 | 武汉爱民制药有限公司 | Aescin medicine composition and its prepn process and use |
| CN101084911A (en) * | 2006-06-08 | 2007-12-12 | 中国科学院上海药物研究所 | Notoginsenoside sodium freezing-dried emulsion and preparation method thereof |
| CN101433544A (en) * | 2007-11-12 | 2009-05-20 | 江苏中康药物科技有限公司 | External-use pharmaceutical composition formulation with antiphlogistic, swelling-dispersing and analgesic functions, and use |
| CN102793664A (en) * | 2012-09-13 | 2012-11-28 | 太极集团有限公司 | Sodium aescinate micro-emulsification injection and preparation method thereof |
| CN104804060A (en) * | 2015-05-07 | 2015-07-29 | 西安蓝绿卓生物科技有限公司 | Preparing method of sodium aescinate, external use preparation comprising same and application thereof |
-
2016
- 2016-04-13 CN CN201610227303.6A patent/CN105878173B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1931176A (en) * | 2005-07-15 | 2007-03-21 | 武汉爱民制药有限公司 | Aescin medicine composition and its prepn process and use |
| CN101084911A (en) * | 2006-06-08 | 2007-12-12 | 中国科学院上海药物研究所 | Notoginsenoside sodium freezing-dried emulsion and preparation method thereof |
| CN101433544A (en) * | 2007-11-12 | 2009-05-20 | 江苏中康药物科技有限公司 | External-use pharmaceutical composition formulation with antiphlogistic, swelling-dispersing and analgesic functions, and use |
| CN102793664A (en) * | 2012-09-13 | 2012-11-28 | 太极集团有限公司 | Sodium aescinate micro-emulsification injection and preparation method thereof |
| CN104804060A (en) * | 2015-05-07 | 2015-07-29 | 西安蓝绿卓生物科技有限公司 | Preparing method of sodium aescinate, external use preparation comprising same and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 七叶皂苷钠搽剂治疗急性闭合性创伤所致肢体肿胀的;高长虹;《中国实用医药》;20131110;第8卷(第31期);15-16页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105878173A (en) | 2016-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6375037B2 (en) | Pharmaceutical composition containing crude drugs (組成) | |
| BR112018003749B1 (en) | LIQUID PHARMACEUTICAL COMPOSITIONS COMPRISING SGLT-2 INHIBITORS, KIT OF PARTS AND PROCESS FOR PRODUCING THE LIQUID PHARMACEUTICAL COMPOSITION | |
| CN111012737A (en) | Flurbiprofen sodium gel and preparation method thereof | |
| WO2014118040A1 (en) | Extract from indigo tinctoria for the topical treatment and prophylaxis of skin disorders | |
| CN105878173B (en) | A kind of Sodium Aescinate liniment | |
| CN106031710B (en) | The injection and preparation method thereof that a kind of fumaric acid fluorine pula is praised | |
| JP2019142856A (en) | Loxoprofen-containing skin external preparation | |
| CN101278929A (en) | Method for preparing medicament containing gambogic acid compounds and clathrate of gambogic acid compounds | |
| CN101816643B (en) | Medicament composition containing diclofenac sodium and acetaminophen | |
| CN101797278A (en) | Tripterygium wilfordii Hook.f total terpenoid vesicles and preparation method thereof | |
| CN108743534B (en) | Tripterine or tripterine derivative vesicle and preparation method thereof | |
| CN105030671B (en) | Methimazole micro emulsion, methimazole micro emulsion gel and its preparation method and application | |
| CN104721234A (en) | Periplaneta Americana extract product ion-activated in-situ gel and preparation method thereof | |
| CN102091284B (en) | Xingnaojing oral emulsion for treating cerebral apoplexy and preparation method thereof | |
| CN107157922A (en) | A kind of otoginsenoside gel and preparation method thereof | |
| CN107126412A (en) | Aescinate B lipidosome gel and preparation method thereof | |
| CN108670950B (en) | Polydatin pharmaceutical composition without organic solvent and preparation method thereof | |
| KR20200111138A (en) | Dexibupropen syrup formulation with improved solubility and stability | |
| CN106943339A (en) | Aescinate A lipidosome gel and preparation method thereof | |
| CN102670624B (en) | Patch for treating rheumatic arthritis and preparation method thereof | |
| CN107157921A (en) | Aescinate A, B lipidosome gels and preparation method thereof | |
| CN101422454B (en) | Omega-3 polyunsaturated fatty acid tanshinone IIA sub-microemulsion and preparation method thereof | |
| CN108355138A (en) | A kind of application of azone in drug transdermal promotees to ooze | |
| CN103989670A (en) | Application of aristolochic acid in preparation of drugs treating rheumatoid arthritis | |
| CN106176606B (en) | sodium aescinate aerosol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Sodium aescinate liniment Effective date of registration: 20200513 Granted publication date: 20181019 Pledgee: Ezhou SME Financing Guarantee Co., Ltd Pledgor: WUHAN AIMIN PHARMACEUTICAL Co.,Ltd. Registration number: Y2020420000016 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20210325 Granted publication date: 20181019 Pledgee: Ezhou SME Financing Guarantee Co.,Ltd. Pledgor: WUHAN AIMIN PHARMACEUTICAL Co.,Ltd. Registration number: Y2020420000016 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right |